In English | En español
Questions About Cancer? 1-800-4-CANCER

Featured Clinical Trials

Highlighted NCI-Supported Cancer Studies < Back to Main

Page Options

  • Print This Page
  • Email This Document

Search Featured Trials

Related Pages

Colon and Rectal Cancer - Featured Clinical Trials

The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:

Continuing Bevacizumab Therapy for Metastatic Colorectal Cancer
(Posted: 03/04/2008) - In this trial, patients with metastatic colorectal cancer that has progressed on first-line therapy containing oxaliplatin and bevacizumab will be treated with the agents irinotecan and cetuximab. The patients will also be randomly assigned to receive continued bevacizumab or no additional bevacizumab.

Treating Colorectal Cancer Liver Metastases
(Posted: 01/16/2007, Updated: 10/23/2007) - In this trial, colorectal cancer patients with six or fewer hepatic metastases will undergo primary surgery and/or ablation and then be treated with oxaliplatin and capecitabine. Half of the patients will receive additional chemotherapy consisting of floxuridine pumped directly into their livers through an arterial catheter and pump.

Measuring Biological Response to Curcumin
(Posted: 03/06/2007) - In this trial, researchers are exploring the ability of a substance called curcumin to affect biomarkers associated with precancerous lesions in the colons of smokers.

Combining Targeted Therapies for Metastatic Colorectal Cancer
(Posted: 08/15/2006, Updated: 02/06/2007) - In this trial, researchers are combining the targeted monoclonal antibody cetuximab (Erbitux) with another targeted drug called sorafenib (Nexavar) to treat patients with metastatic colorectal cancer whose tumors show epidermal growth factor receptor (EGFR) activity.

Gene Therapy for Metastatic Cancer
(Posted: 11/21/2006) - In the trial, researchers will harvest normal T lymphocytes from patients' blood and modify these immune system cells to recognize p53 protein, a common hallmark of many cancers. The modified cells will be enriched in the laboratory and then infused back into the patients.

< Previous  1 2 3 4  Next >